Matin M. Imanguli
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Matin M. Imanguli.
Blood | 2009
Matin M. Imanguli; William D. Swaim; Stacy League; Ronald E. Gress; Steven Z. Pavletic; Frances T. Hakim
Although chronic graft-versus-host disease (cGVHD) is a major long-term complication of allogeneic hematopoietic stem cell transplantation, little is known of its pathogenesis. We have systematically examined oral mucosa among cGVHD patients and determined that the clinical severity of oral cGVHD was correlated with apoptotic epithelial cells, often found adjacent to infiltrating effector-memory T cells expressing markers of cytotoxicity and type I cytokine polarization. Accumulation of T-bet(+) T-cell effectors was associated with both increased proliferation and the expression of the type I chemokine receptor CXCR3. Concurrently, in both infiltrating cells and keratinocytes, we observed increased expression of the CXCR3 ligand MIG (CXCL9) and interleukin-15 (IL-15), type I interferon (IFN)-inducible factors that support the migration, type I differentiation, and expansion of alloreactive effectors. In severely affected mucosa, we observed high levels of MxA, a protein specifically induced by type I IFN, and signal transducer and activator of transcription 1 (STAT1) phosphorylation, a critical step in the IFN-signaling pathway, along with increased numbers of plasmacytoid dendritic cells. These data challenge the current paradigm of cGVHD as a type II cytokine-driven disorder and support the model that oral cGVHD results from type I IFN-driven immigration, proliferation, and differentiation of T-bet(+) type I T effectors. The clinical trials are registered at http://www.clinicaltrials.gov as NCT00331968.
Biology of Blood and Marrow Transplantation | 2010
Matin M. Imanguli; Jane C. Atkinson; Sandra A. Mitchell; Daniele Avila; Rachel J. Bishop; Edward W. Cowen; Manuel B. Datiles; Frances T. Hakim; David E. Kleiner; Michael Krumlauf; Steven Z. Pavletic
Although xerostomia is a commonly reported complaint in patients with chronic graft-versus-host disease (cGVHD), criteria for evaluating the prevalence and characteristics of salivary gland involvement have not been well defined in this patient population. Previous studies also have made no distinction between salivary and mucosal oral cGVHD. We systematically evaluated signs and symptoms of sicca in a large cohort of patients with cGVHD (n = 101) using instruments widely used to study Sjogrens syndrome. Xerostomia was reported in 60 (77%) patients reporting ocular and 52 (67%) patients reporting oral complaints [corrected]. The salivary flow rate was < or =0.2 mL/min in 27%, and < or =0.1 mL/min in 16%. Histopathological changes, consisting of mononuclear infiltration and/or fibrosis/atrophy, were present in all patients with salivary dysfunction. Importantly, there was no correlation of salivary and oral mucosal involvement in cGVHD. Patients with cGVHD-associated salivary gland involvement had diminished oral cavity-specific quality of life and lower body mass index. Salivary gland involvement is a common and clinically distinct manifestation of cGVHD. Formal evaluation of salivary function using standardized criteria is needed, and this could be incorporated as an outcome measure in clinical trials of cGVHD.
Journal of Immunology | 2016
Frances T. Hakim; Sarfraz Memon; Ping Jin; Matin M. Imanguli; Huan Wang; Najibah Rehman; Xiao-Yi Yan; Jeremy J. Rose; Jacqueline W. Mays; Susan Dhamala; Veena Kapoor; William G. Telford; John Dickinson; Sean Davis; David Halverson; Haley B. Naik; Kristin Baird; Daniel H. Fowler; David F. Stroncek; Edward W. Cowen; Steven Z. Pavletic; Ronald E. Gress
Although chronic graft-versus-host disease (CGVHD) is the primary nonrelapse complication of allogeneic transplantation, understanding of its pathogenesis is limited. To identify the main operant pathways across the spectrum of CGVHD, we analyzed gene expression in circulating monocytes, chosen as in situ systemic reporter cells. Microarrays identified two interrelated pathways: 1) IFN-inducible genes, and 2) innate receptors for cellular damage. Corroborating these with multiplex RNA quantitation, we found that multiple IFN-inducible genes (affecting lymphocyte trafficking, differentiation, and Ag presentation) were concurrently upregulated in CGVHD monocytes compared with normal subjects and non-CGVHD control patients. IFN-inducible chemokines were elevated in both lichenoid and sclerotic CGHVD plasma and were linked to CXCR3+ lymphocyte trafficking. Furthermore, the levels of the IFN-inducible genes CXCL10 and TNFSF13B (BAFF) were correlated at both the gene and the plasma levels, implicating IFN induction as a factor in elevated BAFF levels in CGVHD. In the second pathway, damage-/pathogen-associated molecular pattern receptor genes capable of inducing type I IFN were upregulated. Type I IFN-inducible MxA was expressed in proportion to CGVHD activity in skin, mucosa, and glands, and expression of TLR7 and DDX58 receptor genes correlated with upregulation of type I IFN-inducible genes in monocytes. Finally, in serial analyses after transplant, IFN-inducible and damage-response genes were upregulated in monocytes at CGVHD onset and declined upon therapy and resolution in both lichenoid and sclerotic CGVHD patients. This interlocking analysis of IFN-inducible genes, plasma analytes, and tissue immunohistochemistry strongly supports a unifying hypothesis of induction of IFN by innate response to cellular damage as a mechanism for initiation and persistence of CGVHD.
Biology of Blood and Marrow Transplantation | 2016
Matin M. Imanguli; Jane C. Atkinson; Sandra A. Mitchell; Daniele Avila; Rachel J. Bishop; Edward W. Cowen; Manuel B. Datiles; Frances T. Hakim; David E. Kleiner; Michael Krumlauf; Steven Z. Pavletic
In the above mentioned article, the authors have noted an error in the abstract and Results sections. The original text of the abstract reads “Xerostomia was reported by 77% of the patients and was associated with xerophthalmia in all but 1 case.” The correct text should read “Xerostomia was reported in 60 (77%) patients reporting ocular and 52 (67%) patients reporting oral complaints.” In the Results section, the sentence that reads “Overall, 66 patients (86%) gave at least one positive answer on the questionnaire, with 60 (77%) reporting oral complaints and 51 (67%) reporting ocular complaints.” should be corrected to read “Overall, 66 patients (86%) gave at least one positive answer on the questionnaire, with 60 (77%) patients reporting ocular and 52 (67%) patients reporting oral complaints.”
Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology | 2006
Matin M. Imanguli; Steven Z. Pavletic; Jean-Pierre Guadagnini; Jaime S. Brahim; Jane C. Atkinson
Experimental Hematology | 2007
Matin M. Imanguli; Jane C. Atkinson; Kristen E. Harvey; Gerard T. Hoehn; Ok Hee Ryu; Tianxia Wu; Albert Kingman; A. John Barrett; Michael R. Bishop; Richard Childs; Daniel H. Fowler; Steven Z. Pavletic; Thomas C. Hart
Biology of Blood and Marrow Transplantation | 2011
Sandra A. Mitchell; David A. Jacobsohn; Kimberly Powers; Paul A. Carpenter; Mary E.D. Flowers; Edward W. Cowen; Mark M. Schubert; Maria L. Turner; Stephanie J. Lee; Paul Martin; Michael R. Bishop; Kristin Baird; Javier Bolaños-Meade; Kevin L. Boyd; Jane M. Fall-Dickson; Lynn H. Gerber; Jean Pierre Guadagnini; Matin M. Imanguli; Michael Krumlauf; Leslie Lawley; Li Li; Bryce B. Reeve; Janine A. Clayton; Georgia B. Vogelsang; Steven Z. Pavletic
Journal of Oral and Maxillofacial Surgery | 2007
Matin M. Imanguli; Laszlo Karai; Rabie M. Shanti; Donn M. Stewart; Jaime S. Brahim
Biology of Blood and Marrow Transplantation | 2014
Fran Hakim; Ping Jin; Sarfraz Memon; Xiao-Yi Yan; Matin M. Imanguli; Kristin Baird; Edward W. Cowen; David F. Stroncek; Ronald E. Gress; Steven Z. Pavletic
Update on Cancer Therapeutics | 2006
Matin M. Imanguli; Richard Childs